Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened
new avenues towards the development of novel assets to achieve durable immune control
of cancer. Yet, the presence of tumor immune evasion mechanisms represents a challenge
for the development of efficient treatment options. Therefore, combination therapies are
taking the center of the stage in immuno-oncology. Such combination therapies should
boost anti-tumor immune responses and/or target tumor immune escape mechanisms …